These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2317 related items for PubMed ID: 10813727

  • 1. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 2. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM.
    Sangre (Barc); 1998 Jun 01; 43(3):179-84. PubMed ID: 9741222
    [Abstract] [Full Text] [Related]

  • 3. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
    Klimo P, Connors JM.
    Semin Hematol; 1988 Apr 01; 25(2 Suppl 2):34-40. PubMed ID: 2456621
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M, EORTC-GELA H8 Trial.
    N Engl J Med; 2007 Nov 08; 357(19):1916-27. PubMed ID: 17989384
    [Abstract] [Full Text] [Related]

  • 5. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
    Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
    [Abstract] [Full Text] [Related]

  • 6. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M, Ditonno P, Lorusso V, Timurian A, Pellecchia A, Brandi M, Berardi F, Marzullo F.
    Haematologica; 1993 Jan 15; 78(4):230-5. PubMed ID: 7507457
    [Abstract] [Full Text] [Related]

  • 7. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):19-30. PubMed ID: 17097834
    [Abstract] [Full Text] [Related]

  • 8. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G, Cocorocchio E, Peccatori F, Zucca E, Saletti PC, Calabrese L, Pastano R, Pruneri G, Mazzetta C, Ghielmini M, Cavalli F.
    Br J Haematol; 2004 Jun 01; 125(5):584-9. PubMed ID: 15147373
    [Abstract] [Full Text] [Related]

  • 9. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP.
    Semin Oncol; 1990 Feb 01; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [Abstract] [Full Text] [Related]

  • 10. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):765-81. PubMed ID: 15183480
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Aug 01; 30(8):630-4. PubMed ID: 19102946
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A, Gobbi P, Danova M, Giordano M, Pieresca C, Bertoloni D, Brugnatelli S, Ascari E.
    Haematologica; 1993 Aug 01; 78(1):44-8. PubMed ID: 7684012
    [Abstract] [Full Text] [Related]

  • 16. CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease.
    Brusamolino E, Castelli G, Pagnucco G, Orlandi E, Malagó D, Lazzarino M, Bernasconi C.
    Haematologica; 1990 Aug 01; 75(4):340-5. PubMed ID: 1703510
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S, Geara F, Nabbout B, Farah RA, Shabb NS, Hajjar T, Khogali M.
    Radiat Oncol Investig; 1999 Aug 01; 7(6):365-73. PubMed ID: 10644060
    [Abstract] [Full Text] [Related]

  • 19. European experience with ifosfamide in lymphomas.
    von Kalle AK, Schaadt M, Diehl V.
    Semin Oncol; 1989 Feb 01; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 116.